HER2+ Market to Accelerate Substantially by 2034, Predicts DelveInsight | Key Companies - Zymeworks, Jazz Pharmaceuticals, Ambrx, AnBogen Therapeutics, Enliven Therapeutics, Roche
With the improvement of the disease understanding and more research activities, pharmaceutical companies have their potential drug candidates that are being evaluated in clinical trials for the treatment of HER2+. Approval of some of these drug candidates is anticipated to take place during the forecast period, ultimately changing the HER2+ market scenario in the concerned regions.
/EIN News/ -- New York, USA, April 17, 2024 (GLOBE NEWSWIRE) -- HER2+ Market to Accelerate Substantially by 2034, Predicts DelveInsight | Key Companies - Zymeworks, Jazz Pharmaceuticals, Ambrx, AnBogen Therapeutics, Enliven Therapeutics, Roche
With the improvement of the disease understanding and more research activities, pharmaceutical companies have their potential drug candidates that are being evaluated in clinical trials for the treatment of HER2+. Approval of some of these drug candidates is anticipated to take place during the forecast period, ultimately changing the HER2+ market scenario in the concerned regions.
DelveInsight’s HER2+ Market Insights report includes a comprehensive understanding of current treatment practices, emerging HER2+, market share of individual therapies, and current and forecasted HER2+ market size from 2020 to 2034, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the HER2+ Market Report
- As per DelveInsight’s analysis, the HER2+ market is anticipated to grow at a significant CAGR by 2034.
- HER2+ breast cancer accounts for about 15% of all cancers in the United States. In 2023, an estimated 44,000 people were diagnosed with HER2+ breast cancer.
- Leading TROP-2 inhibitor companies such as Zymeworks, Jazz Pharmaceuticals, Ambrx, AnBogen Therapeutics, Enliven Therapeutics, Roche, and others are developing novel HER2+ that can be available in the HER2+ market in the coming years.
- Some of the key HER2+ include Zanidatamab, ARX788, ABT-101, ELVN-002, and Giredestrant, among others.
- In December 2023, the FDA granted Breakthrough Therapy designation for BNT323/DB-1303 for the treatment of advanced endometrial cancer in patients who progressed on or after treatment with immune checkpoint inhibitors.
Discover which therapies are expected to grab the HER2+ market share @ HER2+ Market Report
The market dynamics of HER2+ breast cancer have seen significant shifts over the years, shaped by advancements in treatment options and diagnostic technologies. This subtype of breast cancer accounts for about 20% of all breast cancer cases and has been a focal point for research and pharmaceutical development. With the emergence of targeted therapies such as Herceptin (trastuzumab) and Perjeta (pertuzumab), there has been a remarkable improvement in the prognosis and survival rates for patients with HER2+ breast cancer.
Pharmaceutical companies have been in a race to develop newer, more effective HER2-targeted therapies, leading to a competitive landscape within the HER2+ market. This competition has been a boon for patients, as it has not only expanded treatment options but also driven down costs through the availability of biosimilars. As a result, patients now have access to a range of therapies, from monoclonal antibodies to small molecule inhibitors, offering more personalized treatment approaches.
Another notable aspect of the HER2+ market dynamics is the emphasis on early detection through improved diagnostic tools. Technologies such as HER2 testing have become standard in breast cancer diagnosis, allowing healthcare providers to tailor treatments to the specific characteristics of the tumor. This shift towards precision medicine has not only improved patient outcomes but also influenced the overall landscape of cancer care, paving the way for a more targeted and effective approach to HER2+ breast cancer management.
HER2+ Treatment Market
Currently, there exist various forms of anti-HER2-targeted treatment, including monoclonal antibodies, tyrosine kinase inhibitors, and antibody-drug conjugates. The combination of different anti-HER2 monoclonal antibodies with chemotherapy shows increased effectiveness against HER2-overexpressing cells, displaying a synergistic anti-tumor impact as opposed to using a single form of treatment alone.
ENHERTU, developed through collaboration between Daiichi Sankyo and AstraZeneca, is a targeted antibody combined with a topoisomerase inhibitor. It's used to treat adult patients with unresectable or metastatic NSCLC, as well as approved for gastric and breast cancer. HERCEPTIN, developed by Roche, is an antibody designed to target receptors found on tumor surfaces, preventing cancer spread by blocking these receptors from receiving growth signals. This drug is approved for breast and gastric cancer among other indications. KEYTRUDA, a product of Merck, is a humanized antibody utilized in cancer immunotherapy. It binds to the PD-1 protein, aiding immune cells in killing cancer cells more effectively. Its approvals span a range of cancers, including gastric, colorectal, and NSCLC.
NERLYNX, developed by Puma Biotechnology, is an intracellular kinase inhibitor that binds irreversibly to EGFR, HER2, and HER4. Introduced in July 2017, NERLYNX is used for extended adjuvant treatment in adult patients with early-stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy. TUKYSA, developed by Seagen, is an oral medication functioning as a tyrosine kinase inhibitor targeting the HER2 protein. In laboratory studies, TUKYSA demonstrated the inhibition of HER2 and HER3 phosphorylation, consequently suppressing downstream MAPK and AKT signaling pathways, cell proliferation, and exhibiting anti-tumor effects in HER2-expressing tumor cells.
Learn more about the FDA-approved HER2+ @ HER2+ Drugs
Key Emerging HER2+s and Companies
Some of the drugs in the pipeline include Zanidatamab (Zymeworks/Jazz Pharmaceuticals), ARX788 (Ambrx), ABT-101 (AnBogen Therapeutics), ELVN-002 (Enliven Therapeutics), and Giredestrant (Roche) among others.
Zanidatamab, a HER2-targeted bispecific antibody developed through Zymeworks' exclusive Azymetric platform, binds to two distinct sites on the HER2 protein found on various cancer cells. It is currently undergoing clinical trials as a precision treatment for patients with solid tumors that exhibit HER2 expression. These trials include investigations in biliary tract cancers, breast cancer, and colorectal cancer. The FDA has acknowledged zanidatamab with a Breakthrough Therapy designation for its development in previously treated HER2 gene-amplified biliary tract cancers (BTC), as well as two Fast Track designations—one for its use as a standalone therapy in refractory BTC, and another for its combination with standard chemotherapy in first-line treatment of gastroesophageal adenocarcinoma (GEA).
ARX788, an antibody-drug conjugate targeting HER2, is currently under investigation in numerous clinical trials for breast cancer, gastric/gastroesophageal junction (GEJ) cancer, and other types of solid tumors. It has exhibited promising effectiveness against tumors in various preclinical cancer models, including both high- and low-HER2-expressing breast cancers, ovarian cancer, and gastric cancer. Findings presented at SABCC revealed that ARX788 remains active following treatment with KADCYLA, suggesting potential efficacy post-ENHERTU as well. The FDA has granted Fast Track Designation to ARX788 for HER2+ metastatic breast cancer and Orphan Drug Designation for its use in gastric cancer.
ABT-101, a powerful small molecule kinase inhibitor, targets various cancer-causing kinases such as the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2, also known as ERBB2). Compared to other treatments in clinical development, ABT-101 shows promising therapeutic potential and a notably safer profile. It addresses the urgent medical need for drugs combating HER2-activating mutations (e20i) in HER2-related cancers. AnBogen Therapeutics announced in September 2022 that the US FDA has approved an amendment to the investigational new drug (IND) protocol for its Phase Ib/II trial of ABT-101. Currently, the drug is undergoing evaluation in a Phase IIa clinical trial for HER2 mutant NSCLC. As per the company's pipeline, they are aiming to submit a New Drug Application (NDA) by 2027 for the treatment of HER2 mutant NSCLC.
The anticipated launch of these emerging therapies are poised to transform the HER2+ market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the HER2+ market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about HER2+ clinical trials, visit @ HER2+ Treatment Drugs
HER2+ Overview
HER2+ refers to a specific type of breast cancer characterized by the overexpression of a protein called human epidermal growth factor receptor 2. This protein plays a crucial role in cell growth and division, but when it is overproduced, it can lead to uncontrolled growth of cancer cells. HER2+ breast cancer accounts for about 20% of all breast cancers and tends to be more aggressive than other types. However, advancements in medical research have led to targeted therapies that specifically attack the HER2 protein, offering new hope for patients with this subtype of breast cancer. These targeted treatments, such as Herceptin and Perjeta, have significantly improved survival rates and outcomes for HER2+ breast cancer patients, highlighting the importance of personalized medicine in cancer treatment.
For individuals diagnosed with HER2+ breast cancer, treatment often involves a combination of surgery, chemotherapy, radiation therapy, and targeted therapy. The presence of the HER2 protein can be identified through testing, helping doctors tailor treatment plans to target this specific characteristic of the cancer cells. With ongoing research into new therapies and a better understanding of the molecular mechanisms behind HER2+ breast cancer, the outlook for patients continues to improve. Additionally, awareness campaigns and screening efforts play a vital role in early detection, offering the best chances for successful treatment and recovery.
HER2+ Epidemiology Segmentation
The HER2+ report takes into the account of historical, current, and forecasted HER2+ patient pool. In 2023, there were approximately 3,600 males and 2,200 females affected with HER2-positive gastric cancer in the United States.
The HER2+ market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Incident Cases of Selected Indications
- Total Eligible Patient Pool for HER2+ in Selected Indications
- Total Treated Cases in Selected Indications for HER2+
Download the report to understand what epidemiologists are saying about how HER2+ patient trends in 7MM @ HER2+ Epidemiological Insights
| HER2+ Report Metrics | Details |
| Study Period | 2020–2034 |
| HER2+ Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Key HER2+ Companies | Zymeworks, Jazz Pharmaceuticals, Ambrx, AnBogen Therapeutics, Enliven Therapeutics, Roche, and others |
| Key HER2+ | Zanidatamab, ARX788, ABT-101, ELVN-002, and Giredestrant, among others |
Scope of the HER2+ Market Report
- HER2+ Therapeutic Assessment: HER2+ current marketed and emerging therapies
- HER2+ Market Dynamics: Attribute Analysis of Emerging HER2+ Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, HER2+ Market Access and Reimbursement
Discover more about HER2+ drugs in development @ HER2+ Clinical Trials
Table of Contents
| 1. | HER2+ Market Key Insights |
| 2. | HER2+ Market Report Introduction |
| 3. | HER2+ Market Overview at a Glance |
| 4. | HER2+ Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | HER2+ Treatment and Management |
| 7. | HER2+ Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | HER2+ Marketed Drugs |
| 10. | HER2+ Emerging Drugs |
| 11. | Seven Major HER2+ Market Analysis |
| 12. | HER2+ Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Metastatic HER2-Positive Breast Cancer Market
Metastatic HER2-Positive Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic HER2-positive breast cancer companies including Byondis, Roche, Ambrx, Zymeworks, Jazz Pharmaceuticals, Pfizer, among others.
Metastatic HR+/HER2− Breast Cancer Market
Metastatic HR+/HER2− Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic HR+/HER2-negative breast cancer companies including Merck, Arvinas, Olema Pharmaceuticals, Celcuity, Roche, AstraZeneca, Daiichi Sankyo, Eli Lilly, Sermonix Pharmaceuticals, Genentech, Veru Pharma, DualityBio, BioNtech, Evgen Pharma, Carrick Therapeutics, EQRx, G1 Therapeutics, Immutep, among others.
KRAS Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key KRAS inhibitors companies, including Novartis, Roche, Genentech, Verastem Oncology, Revolution Medicines, Cardiff Oncology, Immuneering Corporation, Jacobio Pharmaceuticals, BridgeBio Pharma, Mirati Therapeutics, Deciphera Pharmaceuticals, Elicio Therapeutics, InventisBio, Gritstone Bio, D3 Bio, among others.
PD/L-1 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD/L-1 inhibitors companies, including Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, among others.
TROP-2 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key TROP-2 inhibitors companies, including Daiichi Sankyo, AstraZeneca, Kelun Biotech, Merck, DualityBio, BioNTech, BiOneCure Therapeutics, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.
